Fig. 7
From: The therapeutic potential of pegylated arginase I treatment in glioblastoma
Transwell-co-cultured BV2 cells protected U87(lf+) against BCT-100; pretreating BV2 with etoposide suppressed such protection. (a) The immunophenotyping of BV2 cells treated with or without mouse IFN-γ or mouse IL-4 for 48 h. *p < 0.05 between groups were compared. (b) (i) Schematic diagrams of experimental setup. (ii) Cytotoxicity responses of U87(lf+) with or without different cytokine-pretreated BV2 transwell co-culture and treated with or without 1 U/ml BCT-100 for 72 h determined by using annexin V/propidium iodide assay. ***p < 0.001 compared between U87(lf+) in M0-, M1-, or M2-polarized BV2 Transwell co-culture and U87(lf+) alone (i.e., not co-cultured with BV2). (c) Trypan blue exclusion assay of BV2 cells treated with PBS or 20 µM etoposide. ***number of viable BV2 treated with 20 µM VP-16 compared to PBS. (d) (i) Schematic diagrams of the experimental setup. (ii-iv) Cytotoxicity responses of U87(lf+) with or without VP-16 pretreated BV2 Transwell co-culture and treated with or without 1 U/ml BCT-100 for 72 h determined by using annexin V/propidium iodide assay. *p < 0.05 compared between U87(lf+) in BV2 Transwell co-culture and U87(lf+) alone. ^p < 0.05 compared between U87(lf+) in BV2 Transwell co-culture pretreated with or without VP-16.
